{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:29:21Z","timestamp":1768087761436,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011928","name":"Ovarian Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.tranon.2024.101914","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T12:44:57Z","timestamp":1709037897000},"page":"101914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-1613","authenticated-orcid":false,"given":"Bonnita","family":"Werner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-8682","authenticated-orcid":false,"given":"Katrin M","family":"Sjoquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-5975","authenticated-orcid":false,"given":"Michelle M","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-6014","authenticated-orcid":false,"given":"Linda","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumitra","family":"Ananda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-9081","authenticated-orcid":false,"given":"Kristina","family":"Warton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-2309","authenticated-orcid":false,"given":"Caroline E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2024.101914_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2021.02.002","article-title":"REZOLVE (ANZGOG-1101): a phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","author":"Sjoquist","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0002","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4143\/crt.2019.700","article-title":"Clinical implications of circulating tumor DNA from ascites and serial plasma in ovarian cancer","volume":"52","author":"Han","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.tranon.2024.101914_bib0003","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ygyno.2021.06.028","article-title":"Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer","volume":"162","author":"Werner","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0004","first-page":"14","article-title":"Transcending blood-opportunities for alternate liquid biopsies in oncology","author":"Werner","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2024.101914_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2024.101914_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jso.25453","article-title":"Palliation of malignant ascites","volume":"120","author":"Hodge","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0007","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0008","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2024.101914_bib0009","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2024.101914_bib0010","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0011","doi-asserted-by":"crossref","first-page":"31047","DOI":"10.1074\/jbc.274.43.31047","article-title":"Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent","volume":"274","author":"Bernatchez","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2024.101914_bib0012","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tranon.2024.101914_bib0013","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","article-title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Gotlieb","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0016","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000499337","article-title":"Liquid biopsy: general concepts","volume":"63","author":"Poulet","year":"2019","journal-title":"Acta Cytol."},{"key":"10.1016\/j.tranon.2024.101914_bib0017","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid biopsies in cancer diagnosis, monitoring, and prognosis","volume":"40","author":"De Rubis","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tranon.2024.101914_bib0018","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.13009","article-title":"Venous thrombosis and cancer: from mouse models to clinical trials","volume":"13","author":"Hisada","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.tranon.2024.101914_bib0019","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2024.101914_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2024.101914_bib0021","doi-asserted-by":"crossref","first-page":"E1826","DOI":"10.1073\/pnas.1519286113","article-title":"Identification of tissue-specific cell death using methylation patterns of circulating DNA","volume":"113","author":"Lehmann-Werman","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tranon.2024.101914_bib0022","doi-asserted-by":"crossref","first-page":"e28141","DOI":"10.1371\/journal.pone.0028141","article-title":"Genome-scale screen for DNA methylation-based detection markers for ovarian cancer","volume":"6","author":"Campan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2024.101914_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250561","article-title":"Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation","volume":"16","author":"Yuwono","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2024.101914_bib0024","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2013-01-479170","article-title":"A mechanistic role for DNA methylation in endothelial cell (EC)-enriched gene expression: relationship with DNA replication timing","volume":"121","author":"Shirodkar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2024.101914_bib0025","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1373\/clinchem.2006.068577","article-title":"Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats","volume":"52","author":"Umetani","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tranon.2024.101914_bib0026","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/1759-7714.13201","article-title":"Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.tranon.2024.101914_bib0027","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1515\/cclm-2020-1465","article-title":"ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma","volume":"59","author":"Perez-Barrios","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.tranon.2024.101914_bib0028","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2018.02.013","article-title":"Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA)","volume":"74","author":"Mehra","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.101914_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","article-title":"Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients","volume":"88","author":"Valpione","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2024.101914_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1586","article-title":"Plasma cell-free DNA quantification is highly correlated to tumor burden in children with neuroblastoma","author":"Wang","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2024.101914_bib0031","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0002-9378(70)90031-1","article-title":"Genesis of ascites in ovarian cancer","volume":"106","author":"Hirabayashi","year":"1970","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.tranon.2024.101914_bib0032","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/cas.14245","article-title":"Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy","volume":"111","author":"Sugimori","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2024.101914_bib0033","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","article-title":"Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival","volume":"25","author":"Baumgartner","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/cjp2.207","article-title":"Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid","author":"Van't Erve","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.tranon.2024.101914_bib0035","article-title":"Prediction for 2-year mortality of metastatic ovarian cancer patients based on surveillance, epidemiology, and end results database","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Surg."},{"key":"10.1016\/j.tranon.2024.101914_bib0036","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1111\/j.1538-7836.2011.04465.x","article-title":"Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus","volume":"9","author":"Swystun","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.tranon.2024.101914_bib0037","article-title":"Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125","volume":"38","author":"Minato","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.tranon.2024.101914_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2022.09.004","article-title":"Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer","author":"Hou","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2024.101914_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262770","article-title":"Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer","volume":"17","author":"Heitz","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2024.101914_bib0040","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-20-3345","article-title":"Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer","volume":"27","author":"Paracchini","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2024.101914_bib0041","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1515\/cclm-2021-1152","article-title":"Circulating cell-free DNA undergoes significant decline in yield after prolonged storage time in both plasma and purified form","volume":"60","author":"Yuwono","year":"2022","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324000391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523324000391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:28:27Z","timestamp":1761845307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523324000391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":41,"alternative-id":["S1936523324000391"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.101914","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.101914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. CCBYLICENSE","name":"copyright","label":"Copyright"}],"article-number":"101914"}}